title: The challenge of obesity in paediatric leukaemia treatment: it is not just size that matters.
abstract: In the last two decades, tremendous advances have been made in the treatment of acute lymphocytic leukaemia (ALL) in children with 5 year 'cure' rates in excess of 90%. The maintenance of remission is due, in part, to individualisation of therapy which must consider age, body size, genetic constitution and the impact of disease on drug disposition and action. This review, focused on treatment of ALL and one of the therapeutic mainstays, 6-mercaptopurine, illustrates the importance of obesity as a modulating factor in dose individualisation.
authors.affiliation: Department of Pediatrics and Pharmacology, University of Missouri Kansas City, Kansas City, Missouri, USA Divisions of Hematology/Oncology, Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, The Children's Mercy Hospital, Kansas City, Missouri.
authors.forename: Jaszianne
authors.initials: J
authors.lastname: Tolbert
authors.affiliation: Department of Pediatrics and Pharmacology, University of Missouri Kansas City, Kansas City, Missouri, USA Center for Children's Healthy Lifestyles and Nutrition, The Children's Mercy Hospital, Kansas City, Missouri, USA.
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Kearns
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D063766:Pediatric Obesity / Q000188:drug therapy* / Q000503:physiopathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D015122:Mercaptopurine
keywords: Childhood Leukemia; Drug Dosing; Obesity